Polycystic Ovary Syndrome (PCOS) and In Vitro Fertilization (IVF): A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1

This study has been terminated.
Sponsor:
Information provided by:
Institut Universitari Dexeus
ClinicalTrials.gov Identifier:
NCT00883766
First received: April 17, 2009
Last updated: July 19, 2012
Last verified: October 2010
  Purpose

The aim of this study is to compare two different IVF-stimulation protocols in patients affected by PCOS: the use of a Gonadotropin-releasing hormone (GnRH) - antagonist starting on day 1 of controlled ovarian hyperstimulation (COH) versus a standard long agonist protocol; in order to assess whether it affects the number and quality of Metaphase II (MII) oocytes while reducing the risk of hyperstimulation. Since PCOS patients are also likely to be insulin resistant we also aim to evaluate how metformin affects tha IVF stimulation outcome.


Condition Intervention
Polycystic Ovary Syndrome
In Vitro Fertilization
Other: Controlled ovarian hyperstimulation for IVF with a long agonist protocol
Other: Controlled ovarian hyperstimulation for IVF with an antagonist protocol

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: PCOS and IVF: A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1

Resource links provided by NLM:


Further study details as provided by Institut Universitari Dexeus:

Primary Outcome Measures:
  • Number of Oocytes MII retrieved per patient [ Time Frame: 1 Day ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Fertilization rates [ Time Frame: 24 hours after pick-up ] [ Designated as safety issue: No ]
  • Clinical pregnancy rates [ Time Frame: 4 weeks after pick-up ] [ Designated as safety issue: No ]
  • Incidence of OHSS [ Time Frame: From ovulation triggering to two weeks after pick-up ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 172
Study Start Date: April 2009
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Long agonist protocol Other: Controlled ovarian hyperstimulation for IVF with a long agonist protocol

Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio <4.5

Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days

Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm

Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)

Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound

Day before HCG: stop rFSH

Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)

Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C

Day 7 after pick-up: ultrasound, patient evaluation.

Day 14 after pick-up: HCG in blood

Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive

(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)

Experimental: Antagonist protocol Other: Controlled ovarian hyperstimulation for IVF with an antagonist protocol

Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio <4.5

Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm

Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)

Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO

Day before HCG: stop rFSH + cetrorelix

Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)

Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C

Day 7 after pick-up: ultrasound, patient evaluation.

Day 14 after pick-up: HCG in blood

Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)


Detailed Description:

Hejinen et al (1) recently conducted a meta-analysis to compare outcomes of conventional IVF in women presenting with polycystic ovary syndrome (PCOS) and non-PCOS patients. They compared nine RCTs reporting data on 458 PCOS patients (793 cycles) and 694 matched controls (1116 cycles) and concluded that in PCOS there is an increased cancellation rate, but more oocytes retrieved per pick-up and a lower fertilization rate. Overall, PCOS and control patients achieved similar pregnancy and live birth rates per cycle. The incidence of ovarian hyperstimulation syndrome (OHSS) after oocyte retrieval was rarely reported.

Our results are in accordance with this meta-analysis. Therefore, if the pregnancy and abortion rates in PCOS and controls do not differ, the main problem when dealing with PCOS in IVF is OHSS. This condition can be approached by using an antagonist instead of an agonist, by changing the kind of ovulation trigger and by co-treating patients with metformin.

  • One of the currently debatable issues regarding the use of GnRH antagonists refers to the timing of GnRH antagonist initiation. A fixed protocol starting antagonist arbitrarily on Day 6 of stimulation has been used in all introductory comparative trials employing a daily antagonist administration (2). Following these trials, a flexible antagonist initiation by a follicle of 14-15 mm has been evaluated. Currently, initiation of antagonist in the early follicular phase in PCOS patients has been performed by Lainas and coll. (3) who treated patients with PCOS either with a long GnRH agonist scheme or a fixed day-1 GnRH antagonist protocol and concluded that initiation of GnRH antagonist concomitantly with recombinant FSH on day 1 is associated with an earlier follicular growth and a different hormonal environment during the follicular phase when compared with the long agonist protocol. This may lead to a reduction in the incidence of OHSS.
  • Over the past 15 years, it has become increasingly recognized that insulin resistance is central to the pathogenesis of the PCOS (4). Metformin, a biguanide insulin-lowering agent, has been extensively investigated in the management of PCOS. Two recent systematic reviews (5, 6) demonstrated that metformin improves reproductive function of some women with PCOS. Metformin also appeared to improve the outcomes of ovulation induction therapies when combined with clomiphene and gonadotrophin. Tang et al. recently studied PCOS overweight patients undergoing IVF to whom they administered 850 mg bid or placebo 28 days prior to the stimulation (7). They concluded that short-term co-treatment with metformin for patients with PCOS undergoing IVF/ICSI cycles does not improve the response to stimulation but significantly improves the pregnancy outcome and reduces the risk of OHSS.

The aim of this study is to verify if using an antagonist the number and quality of MII oocytes is equal compared to a standard long agonist protocol while reducing the risk of hyperstimulation.

Outcome measures:

Primary endpoints:

  • Oocytes MII Secondary endpoints
  • Fertilization rates
  • Pregnancy rates
  • Miscarriage rates
  • Incidence of OHSS
  Eligibility

Ages Eligible for Study:   18 Years to 37 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • PCOS patients according to the Rotterdam consensus criteria
  • Presence of both ovaries
  • Absence of endometriomas detected at ultrasound
  • FSH < 10 IU/L on day 3 of the cycle
  • E2 < 80 pg/mL, and Pg < 1.6 ng/mL at initiation of stimulation

Exclusion Criteria:

  • Congenital adrenal hyperplasia
  • Cushing's syndrome
  • Androgen-producing tumours
  • Hyperprolactinaemia and thyroid dysfunction
  • Age > 38 years
  • Serum FSH levels > 10 mIU/ml
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00883766

Locations
Spain
Institut Universitari Dexeus
Barcelona, Spain, 08028
Sponsors and Collaborators
Institut Universitari Dexeus
Investigators
Principal Investigator: Fulvia Mancini, M.D. PhD Department of Obstetric, Gynecology and Reproductive Medicine
  More Information

Additional Information:
Publications:
Responsible Party: Fulvia Mancini, Departamento de Obstetricia, Ginecologia y Reproducción
ClinicalTrials.gov Identifier: NCT00883766     History of Changes
Other Study ID Numbers: DEX002
Study First Received: April 17, 2009
Last Updated: July 19, 2012
Health Authority: Spain: Ethics Committee

Keywords provided by Institut Universitari Dexeus:
Polycystic Ovary Syndrome
GnRH Antagonist
Long Agonist Protocol
OHSS

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Ovarian Cysts
Cysts
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases

ClinicalTrials.gov processed this record on August 26, 2014